BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Jiannis Vlachogiannakos, George V. Papatheodoridis. HBV: Do I treat my immunotolerant patients?Liver International 2016; 36: 93 doi: 10.1111/liv.12996
2
George V. Papatheodoridis, Vana Sypsa, George Dalekos, Cihan Yurdaydin, Florian van Boemmel, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Nikolaos Gatselis, Onur Keskın, Maria Lehretz, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationJournal of Hepatology 2018; 68(6): 1129 doi: 10.1016/j.jhep.2018.01.031
3
George V. Papatheodoridis, George N. Dalekos, Cihan Yurdaydin, Maria Buti, John Goulis, Pauline Arends, Vana Sypsa, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskın, Savvoula Savvidou, Bettina E. Hansen, Christos Papaioannou, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirJournal of Hepatology 2015; 62(2): 363 doi: 10.1016/j.jhep.2014.08.045
4
Yuanyuan Sun, Yanhong Wang, Mengmeng Li, Kailiang Cheng, Xinyu Zhao, Yuan Zheng, Yan Liu, Shaoyuan Lei, Li Wang. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysisBMJ Open 2018; 8(2): e020490 doi: 10.1136/bmjopen-2017-020490
5
Yinghua Zhang, Chuanfang Wang, Hui Li, Yuanyuan Ding. Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis BMedicine 2019; 98(3): e13929 doi: 10.1097/MD.0000000000013929
6
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II RecommendationsJournal of Clinical and Experimental Hepatology 2020; 10(1): 43 doi: 10.1016/j.jceh.2019.09.007
7
George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BHepatology 2017; 66(5): 1444 doi: 10.1002/hep.29320
8
Kyu Sik Jung, Seung Up Kim, Kijun Song, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Kwang-Hyub Han. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapyHepatology 2015; 62(6): 1757 doi: 10.1002/hep.28115
9
Kung-Hao Liang, Chao-Wei Hsu, Ming-Ling Chang, Yi-Cheng Chen, Ming-Wei Lai, Chau-Ting Yeh. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis BJournal of Infectious Diseases 2016; 213(6): 966 doi: 10.1093/infdis/jiv547
10
Yong-Wei Li, Feng-Cai Yang, Hui-Qiong Lu, Jiong-Shan Zhang. Hepatocellular carcinoma and hepatitis B surface proteinWorld Journal of Gastroenterology 2016; 22(6): 1943-1952 doi: 10.3748/wjg.v22.i6.1943
11
Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino, Hie-Won Hann. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cureWorld Journal of Hepatology 2019; 11(1): 65-73 doi: 10.4254/wjh.v11.i1.65
12
Evangelos Cholongitas, Ioannis Goulis, Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou, Evangelos Akriviadis. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrenceTransplant International 2014; 27(10): 1022 doi: 10.1111/tri.12370
13
George V. Papatheodoridis, Vana Sypsa, George N. Dalekos, Cihan Yurdaydin, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, Heng Chi, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Theodoros Voulgaris, Nikolaos Gatselis, Onur Keskin, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Ramazan Idilman, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BJournal of Hepatology 2020; 72(6): 1088 doi: 10.1016/j.jhep.2020.01.007
14
Walid S. Ayoub, Paul Martin, Pietro Lampertico. Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?Current Hepatology Reports 2015; 14(4): 279 doi: 10.1007/s11901-015-0279-1
15
Jiannis Vlachogiannakos, George V. Papatheodoridis. Hepatitis B: Who and when to treat?Liver International 2018; 38: 71 doi: 10.1111/liv.13631
16
Mi Na Kim, Seong Gyu Hwang, Kyu Sung Rim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovirLiver International 2017; 37(12): 1788 doi: 10.1111/liv.13450
17
Peipei Ren, Zhujun Cao, Ruidong Mo, Yuhan Liu, Lichang Chen, Ziqiang Li, Tianhui Zhou, Jie Lu, Yunye Liu, Qing Guo, Rong Chen, Huijuan Zhou, Xiaogang Xiang, Wei Cai, Hui Wang, Shisan Bao, Yumin Xu, Honglian Gui, Qing Xie. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high riskExpert Opinion on Biological Therapy 2018; 18(10): 1085 doi: 10.1080/14712598.2018.1518423
18
Jiannis Vlachogiannakos, George V. Papatheodoridis. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?Liver International 2015; 35: 100 doi: 10.1111/liv.12719
19
Alberto Ferrarese, Alberto Zanetto, Martina Gambato, Ilaria Bortoluzzi, Elena Nadal, Giacomo Germani, Marco Senzolo, Patrizia Burra, Francesco Paolo Russo. Liver transplantation for viral hepatitis in 2015World Journal of Gastroenterology 2016; 22(4): 1570-1581 doi: 10.3748/wjg.v22.i4.1570
20
George Papatheodoridis, George Dalekos, Vana Sypsa, Cihan Yurdaydin, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskin, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyJournal of Hepatology 2016; 64(4): 800 doi: 10.1016/j.jhep.2015.11.035
21
Hye Won Lee, Sang Hoon Ahn. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patientsWorld Journal of Gastroenterology 2016; 22(37): 8314-8321 doi: 10.3748/wjg.v22.i37.8314
22
George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry LA. Janssen, Thomas Berg, Pietro Lampertico. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BJournal of Hepatology 2020;  doi: 10.1016/j.jhep.2020.06.011